Mega Genomics Past Earnings Performance
Past criteria checks 2/6
Mega Genomics's earnings have been declining at an average annual rate of -29.3%, while the Healthcare industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 8.7% per year. Mega Genomics's return on equity is 4.8%, and it has net margins of 20%.
Key information
-29.3%
Earnings growth rate
n/a
EPS growth rate
| Healthcare Industry Growth | 11.3% |
| Revenue growth rate | 8.7% |
| Return on equity | 4.8% |
| Net Margin | 20.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Returns On Capital Signal Tricky Times Ahead For Mega Genomics (HKG:6667)
Aug 28
Some Investors May Be Worried About Mega Genomics' (HKG:6667) Returns On Capital
May 03Calculating The Intrinsic Value Of Mega Genomics Limited (HKG:6667)
Feb 20Mega Genomics Limited's (HKG:6667) Share Price Could Signal Some Risk
Aug 12A Look At The Fair Value Of Mega Genomics Limited (HKG:6667)
Nov 07Revenue & Expenses Breakdown
How Mega Genomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 160 | 32 | 59 | 0 |
| 31 Mar 24 | 156 | 31 | 60 | 0 |
| 31 Dec 23 | 151 | 30 | 61 | 0 |
| 30 Sep 23 | 149 | 15 | 82 | 0 |
| 30 Jun 23 | 147 | 0 | 103 | 0 |
| 31 Mar 23 | 146 | -9 | 103 | 0 |
| 31 Dec 22 | 146 | -18 | 104 | 0 |
| 30 Sep 22 | 192 | 22 | 84 | 0 |
| 30 Jun 22 | 238 | 62 | 65 | 0 |
| 31 Mar 22 | 238 | 70 | 58 | 0 |
| 31 Dec 21 | 237 | 79 | 52 | 0 |
| 31 Dec 20 | 203 | 79 | 35 | 0 |
| 31 Dec 19 | 124 | 30 | 27 | 0 |
Quality Earnings: 6667 has high quality earnings.
Growing Profit Margin: 6667 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6667's earnings have declined by 29.3% per year over the past 5 years.
Accelerating Growth: 6667 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 6667 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (-11.6%).
Return on Equity
High ROE: 6667's Return on Equity (4.8%) is considered low.